NCI’s Clinical Trials Cooperative Groups National Meetings Report

Summer 2013

In This Issue:
American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Pediatric Hematology/Oncology (ASPHO), ASCO Gastrointestinal & Genitourinary Cancers Symposia, International Conference on Malignant Lymphoma, Society of Gynecologic Oncologists (SGO), and Others

Cooperative Group Abstracts:
Breast Cancer
CNS Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Leukemia, Myelodysplasia, and Transplantation
Lung Cancer
Lymphoma and Plasma Cell Disorders
Melanoma/Skin Cancers
Sarcoma/Bone and Soft Tissue Cancers
Other Cancer

NCI Abstracts:
DCTD/DCP Abstracts

The Clinical Trials Cooperative Group Program, sponsored by the National Cancer Institute (NCI), is designed to promote and support clinical trials of new cancer treatments, cancer control and prevention strategies, quality-of-life issues during and after interventions, as well as cancer imaging trials that target therapy, surveillance, and biomarkers of therapeutic responses. An issue of this report will be distributed biannually in Summer (post AMI, AACR, ASCO, SGO, and SNM) and in Winter (post ASCO Breast Symposium, ASH, ACRIN, ASTRO, ISQOL, RSNA, SABCS and AMI/SMI joint meeting) to highlight the research presentations of the Cooperative Groups and the supporting activities of NCI investigators from the Division of Cancer Treatment and Diagnosis - Cancer Therapy Evaluation Program, Cancer Diagnosis Program, Cancer Imaging Program and Radiation Research Program, and from the Division of Cancer Prevention.

Research Highlights in this Issue:

**GOG-0240**: This phase III trial involved a 2x2 randomization of two chemotherapy arms, paclitaxel/carboplatin vs. paclitaxel/topotecan with a secondary randomization to bevacizumab. In 2012, the DSMB review determined non-superiority of the platinum-free arm and the study continued until the 2013 analysis for the effect of the addition of bevacizumab (given 15 mg/kg with chemotherapy every 3 weeks until progression of disease). Chemotherapy + bevacizumab was superior in overall survival (OS), 17 v. 13.3 months (HR 0.71, CI 0.54-0.94; p=0.0035), and progression-free survival (PFS), 8.2 v 5.9 months (HR 0.67, CI 0.54-0.82; p=0.0002). This is the first randomized phase III study in recurrent cervical cancer to yield an OS advantage. SAEs were increased in the bevacizumab arm as expected for bevacizumab toxicity (thromboembolism, GI/GU fistula); quality of life was lower, but this did not reach significance.

**RTOG-0825**: RTOG-0825 evaluated if addition of bevacizumab to standard chemoradiation (CRT) improved overall survival (OS) or progression-free survival (PFS) in newly diagnosed glioblastoma multiforme (GBM). 637 patients were randomized to the standard CRT + placebo or standard CRT + bevacizumab. At progression, patients were allowed to crossover or continue bevacizumab. Secondary analyses evaluated impact of MGMT methylation and prognostic 9-gene signature status. No difference was found between arms for OS (median 16.1 vs. 15.7 months, p = 0.11). PFS was extended for the CRT + bevacizumab arm (7.3 vs. 10.7 months, p = 0.004). Patients with MGMT methylation had superior OS (23.2 vs. 14.3 mo, p < 0.001) and PFS (14.1 vs. 8.2 mo, p < 0.001), but neither the 9-gene signature nor MGMT methylation predicted selective benefit for bevacizumab treatment.
Breast Cancer

**ACOSOG/Alliance**


Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, NSABP, SWOG

Protocol(s): ACOSOG-Z1071

**CALGB/Alliance**


Protocol(s): CALGB-40601


Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, NCIC Clinical Trials Group, SWOG

Protocol(s): CALGB-49907


Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG

Protocol(s): C9741
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/501?sid=211d90d6-54e6-40ec-951b-49deb5d6be8c
Other Participant(s) in the Trial: SWOG
Protocol(s): CALGB-40601

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9581?sid=985b67e7-cc5b-40f4-bf45-2f2c35c6bf0
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance
Protocol(s): CALGB-40502

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1007?sid=9be34414-e040-4be0-b71e-0184942113f8
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG
Protocol(s): CALGB-40101

ECOG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6527?sid=50f97193-0ab7-4c5b-ac14-3cdfb8756fe5
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance
Protocol(s): E5103

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9508?sid=50f97193-0ab7-4c5b-ac14-3cdfb8756fe5
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance
Protocol(s): E5103

Protocol(s): E2Z02
NCCTG/Alliance

Protocol(s): N0337, N98-32-52

Protocol(s): NCCTG N9831

Protocol(s): N0937

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCIC Clinical Trials Group, SWOG
Protocol(s): NCCTG N9831

NCIC Clinical Trials Group

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, SWOG
Protocol(s): NCIC-MA.27

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, NSABP, SWOG
Protocol(s): NCIC-MA.32
**NSABP**


http://meeting.asccopubs.org/cgi/content/abstract/31/15_suppl/TPS666?sid=1b1838f1-75c0-4ee2-a01a-d0e14a84e3b6

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG, SWOG

Protocol(s): NSABP-B-43


http://meeting.asccopubs.org/cgi/content/abstract/31/15_suppl/TPS1139?sid=dda96f3c-1392-45e1-8f3d-49b265f85539

Other Participant(s) in the Trial: ECOG, RTOG, SWOG

Protocol(s): NSABP-B-47


http://meeting.asccopubs.org/cgi/content/abstract/31/15_suppl/1000?sid=c01c5256-b53f-468e-9340-9e6d81a131e2

Protocol(s): NSABP-B-32


Protocol(s): NSABP-B-28

**SWOG**


http://meeting.asccopubs.org/cgi/content/abstract/31/18_suppl/CRA1008?sid=835f275-1d05-477f-a0df-74b1b9f3267c2

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, NCIC Clinical Trials Group

Protocol(s): S0221
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS657?sid=ecc4f723-290c-4442-bf25-8832e4fd792
Other Participant(s) in the Trial: NSABP
Protocol(s): S1207

CNS Cancer

NCCTG/Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2046?sid=c613b886-1b1c-45b2-a5cd-091e30bc56b1
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance
Protocol(s): N0874

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2014?sid=165fe81a-424a-4104-aacf-b90d52c885c2
Protocol(s): N0572

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1596?sid=b80465e4-4a27-bb84709
Protocol(s): N0577

RTOG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2003?sid=1e3a5449-e458-45f7-85c9-6fd094f36e71
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance
Protocol(s): RTOG-0825

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2047?sid=36a70aee-e4d6-48c1-b4a0-9e0431780ee
Protocol(s): RTOG 0913
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2008?sid=201ee576-05fb-4896-b30f-97416cf699e5
Protocol(s): RTOG-0424

http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/1?sid=d1ab9092-14cb-4024-94e2-ccd82885e424
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance
Protocol(s): RTOG-0825

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2033?sid=6d834dea-b6a3-49f3-90ee-52d296c190e5
Protocol(s): RTOG-0227

http://meeting.ascopubs.org/cgi/content/abstract/31/18_suppl/LBA2010?sid=d1415c23-5af0-428a-97d7-3b325eb06c7f
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance
Protocol(s): RTOG-0825

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2004?sid=21deb172-24a5-4900-9971-2c686b279728
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance
Protocol(s): RTOG-0825

Gastrointestinal Cancer

CALGB/Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11011?sid=8da84e74-5d65-4c40-a3e7-7ac4b4d622c3
Protocol(s): CALGB-80203
Other Participant(s) in the Trial: ECOG, NCCTG/Alliance, SWOG
Protocol(s): CALGB-80405

Other Participant(s) in the Trial: ECOG
Protocol(s): CALGB-80303

ECOG

Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, NSABP, SWOG
Protocol(s): E3201

Protocol(s): E2Z02

NCCTG/Alliance

Protocol(s): N0849

Protocol(s): N08CB
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NSABP, SWOG Protocol(s): N0147

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NSABP, SWOG Protocol(s): N0147

McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lopa SH, O'Connell MJ, Wolmark N: A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab for patients with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: Updated results of NSABP C-10 with definitive survival analysis. J Clin Oncol 2013; 31(4 suppl): Abst. 468. [Link](http://meeting.ascopubs.org/cgi/content/abstract/31/4_suppl/468?sid=f8ae2a0d-c5c5-41c6-8b08-b79b6945e41)
Protocol(s): NSABP-C-10

Renfro LA, Grothey A, Saltz L, André T, Labianca R, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ: Accent-based nomograms (NGs) to predict time to recurrence (TTR) and overall survival (OS) in stage III colon cancer (CC). J Clin Oncol 2013; 31(15 suppl): Abst. 3618. [Link](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3618?sid=4ec5d27b-719d-47c3-9be4-9ed9bdc0ec53)
Other Participant(s) in the Trial: NCCTG/Alliance Protocol(s): NSABP-C-04, NSABP-C-05, NSABP-C-06, NSABP-C-07

Lawrence YR, Moughan J, Magliocco A, Klimowicz A, Regine WF, Mowat RB, DiPetrillo TA, Small W, Winter K, Guha C, Crane C, Dicker AP: Elevated expression of mismatch repair enzyme MLH1 is associated with prolonged overall survival in resected pancreatic cancer treated with adjuvant chemoradiation, a biomarker analysis of RTOG 9704. American Association for Cancer Research (AACR), Washington, DC, Apr 2013. Abst. 3553. [Link](http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3086&sKey=100cd1c8-60e0-47d6-8d0e-b53ff7878218cKey=04e08ca1-de40-4649-bf37-0ccf7e033790&mKey=%7b9B2D28E7-24A0-466F-A3C9-07C21F6E9BC9%7d)
Other Participant(s) in the Trial: ECOG, SWOG Protocol(s): RTOG-9704

Protocol(s): RTOG-0246
**SWOG**


[http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS4145?sid=4f0d8a35-ddf9-f4c8-8e55-e72637de6aa2](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS4145?sid=4f0d8a35-ddf9-f4c8-8e55-e72637de6aa2)

Protocol(s): S1115


[http://www.aspo.org/annual_meeting](http://www.aspo.org/annual_meeting)

Protocol(s): S0820

**Genitourinary Cancer**

**CALGB/Alliance**


[http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11053?sid=30653c8d-10d0-4e94-b908-7356ed3c64b](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/11053?sid=30653c8d-10d0-4e94-b908-7356ed3c64b)

Other Participant(s) in the Trial: ECOG

Protocol(s): CALGB-90401


[http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4520?sid=a910434a-08d0-4365-9c6c-4ea10a5b5251](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/4520?sid=a910434a-08d0-4365-9c6c-4ea10a5b5251)

Other Participant(s) in the Trial: ECOG, NCIC Clinical Trials Group

Protocol(s): CALGB-90206


[http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/27?sid=ebf90eba-f9fa-4bc6-804f-c8912314d7de](http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/27?sid=ebf90eba-f9fa-4bc6-804f-c8912314d7de)

Other Participant(s) in the Trial: ECOG, NCIC Clinical Trials Group, RTOG, SWOG

Protocol(s): CALGB-90202

**ECOG**

McDermott DF, Manola J, Pins MR, Flaherty KT, Atkins MB, Dutcher JP, George DJ, Margolin KA, DiPaola RS: The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol 2013; 31(15 suppl): Abst. 345.

[http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/345?sid=87c62cf2-97ad-4db8-a8b4-47bee1a5f95c](http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/345?sid=87c62cf2-97ad-4db8-a8b4-47bee1a5f95c)

Other Participant(s) in the Trial: CALGB/Alliance, SWOG

Protocol(s): E2804
RTOG
Protocol(s): RTOG-0831

SWOG
Other Participant(s) in the Trial: CALGB/Alliance, ECOG
Protocol(s): INT-0080 (SWOG-8710)

Other Participant(s) in the Trial: CALGB/Alliance
Protocol(s): SWOG-9217

Protocol(s): S0000C

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG
Protocol(s): S0000

Protocol(s): S0000C

Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance, RTOG
Protocol(s): S0000
Gynecologic Cancer

GOG

Protocol(s): GOG-LAP2

Protocol(s): GOG-0218

Protocol(s): GOG-0280

Protocol(s): GOG-0229H

Protocol(s): GOG-0218

Protocol(s): GOG-0218

Protocol(s): GOG-0218
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5534?sid=22e1cc96-1545-4e87-a8fb-e17adb4ddcfd

Other Participant(s) in the Trial: NCCTG/Alliance, SWOG
Protocol(s): GOG-0095, GOG-0114, GOG-0128G, GOG-0152, GOG-0162, GOG-0172, GOG-0175, GOG-0182, GOG-111

Protocol(s): GOG-0256

Protocol(s): GOG-0182

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS3121?sid=949ab761-59af-467e-ab2e-fce772f5acd4
Protocol(s): GOG-0265

Protocol(s): GOG-LAP2


Other Participant(s) in the Trial: ECOG, SWOG
Protocol(s): GOG-0114, GOG-0132

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5527?sid=a6734e19-dfc4-4d4-ba5a-3b1ea4e3b07e
Protocol(s): GOG-0076-GG
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/3077?sid=f0862b02-5848-4837-a425-3d32b7d64bd8
Protocol(s): GOG-9925

Protocol(s): GOG-0218

Protocol(s): GOG-0218

Protocol(s): GOG-0210, GOG-8022

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/5530?sid=1281001ebf60-47d7-9769-ee2cf36d667d
Other Participant(s) in the Trial: SWOG
Protocol(s): GOG-0120, GOG-0123, GOG-0165, GOG-0191, GOG-85

Protocol(s): GOG-0182

Other Participant(s) in the Trial: ECOG, SWOG
Protocol(s): GOG-0114, GOG-0172
Other Participant(s) in the Trial: ECOG, GEICO
Protocol(s): GOG-0240

Other Participant(s) in the Trial: ECOG, GEICO
Protocol(s): GOG-0240

Head and Neck Cancer

ACOSOG/Alliance

Protocol(s): ACOSOG-Z0360

ECOG

Burtness BA, Lee J, Yang D, Zhu F, Garcia JJ, Forastiere AA, Chung CH: Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. J Clin Oncol 2013; 31(15 suppl): Abst. 6028. http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6028?sid=e4f4e8aa-1ecc-45f6-9ebf-6984f9a6e9ac
Protocol(s): E5397

Protocol(s): E1308

Protocol(s): E1395, E3301
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6081?sid=14d325cd-837b-4af8-826e-63b7850b9b04
Protocol(s): E2303

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6016?sid=740a3dec-f680-4685-aee3-fd70c7c2d60a
Protocol(s): E5397

**NCCTG/Alliance**

http://www.redjournal.org/article/S0360-3016(12)03772-8/fulltext
Protocol(s): N09C6

**RTOG**

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6007?sid=21f76982-2274-4b2a-bee9-bd39a58033f9
Protocol(s): RTOG-0129, RTOG-0234, RTOG-0522

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS6099?sid=02bb23f9-9f67-431b-b70f-a76a9f26579d
Other Participant(s) in the Trial: ECOG
Protocol(s): RTOG-1216

**Leukemia, Myelodysplasia, and Transplantation**

**CALGB/Alliance**

https://b-com.mci-group.com/EventProgramme/EHA18.aspx (NOT A DIRECT LINK)
Protocol(s): CALGB-20202
http://www.nature.com/clpt/journal/v93/n1s/pdf/clpt2012256a.pdf
Protocol(s): CALGB-10105

COG

http://hsl.med.nyu.edu/facbib-results/author/bhatlt01?src=medical
Protocol(s): AALL0331

http://www.nature.com/modpathol/journal/v26/n2s/pdf/modpathol201313a.pdf
Protocol(s): AAML0431

ECOG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7126?sid=9105e93a-53f7-4691-ab45-c046757e26e
Protocol(s): E1905

SWOG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7028?sid=2dd82822-93ed-482a-b494-a65bc141dd1b
Protocol(s): S0919
http://www.postersessiononline.eu/pr/aula_poster.asp?congreso=602733790
Protocol(s): S0112, S0301, SWOG-9031, SWOG-9333

Lung Cancer

ACOSOG/Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7502
Protocol(s): ACOSOG-Z4032

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7524
Protocol(s): ACOSOG-Z4032

http://www.aats.org/annualmeeting/Program-Books/2013/LB6.coi
Protocol(s): ACOSOG-Z0030

ACRIN

Commean PK, Rathmell JM, Riley TL, Clark KW, Prior FW: A query tool for investigator access to the metadata and CT images of the National Lung Screening Trial. Society for Imaging Informatics in Medicine (SIIM), Grapevine-Dallas, TX, Jun 2013. 
http://www.siim2013.org/abstracts/3_BADM_Commean.html
Protocol(s): ACRIN-6654

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7525
Protocol(s): ACRIN-6654

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1563
Protocol(s): ACRIN-6654
http://www.srnt.org/conferences/SRNT_2013_Abstracts_1-Modified.pdf
Protocol(s): ACRIN-6654

Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7510?sid=71e4c947-7e48-4d49-82ae-cb1c9c1b88ea
Other Participant(s) in the Trial: CALGB/Alliance, NCCTG/Alliance, SWOG
Protocol(s): CALGB-30103, CALGB-9033, CALGB-9732, NCCTG-862051, NCCTG-892051, NCCTG-932053

CALGB/Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7506?sid=3204ebb7-e5d3-4684-ab2e-9ed3beee6bc33
Protocol(s): CALGB-30504

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8039?sid=7a0ce0eb-b5ae-4fdc-a77f-71be781bb655
Protocol(s): CALGB-30406

ECOG

Aggarwal C, Dahlberg SE, Hanna NH, Kolesar J, Hirsch F, Ramalingam SS, Schiller JH: Exploratory biomarker analyses from ECOG 4508: Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2013; 31(15 suppl): Abst. 8106.
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8106?sid=bc974b89-3096-4bfa-bfd2-3c6bf3370c13
Protocol(s): E4508

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8046?sid=8d6b8803-dcde-4593-8709-41376a4411f5
Protocol(s): E4599
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7508?sid=bea83189-fbee-4190-8a8e-952401aeb275
Protocol(s): E1508

NCCTG/Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7509?sid=f86c42bd-cca1-4de3-8743-75e37bd17763
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance, ECOG
Protocol(s): N0923

RTOG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7501?sid=edeacee8-f51f-416f-9ee2-a7d2c0cb8a8fa
Other Participant(s) in the Trial: CALGB/Alliance, ECOG, NCCTG/Alliance
Protocol(s): RTOG-0617

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7523?sid=f4aa2776-f41c-45e9-829d-ea636e8971b6
Protocol(s): RTOG-0618

SWOG

http://conference-cast.com/STS/common/presentations.aspx/1/2/30
Other Participant(s) in the Trial: ACOSOG/Alliance, CALGB/Alliance, ECOG, NCCTG/Alliance, NCIC Clinical Trials Group
Protocol(s): S0220
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7511?sid=3a1cfd25-0bd8-405d-8146-0386698af5d3
Protocol(s): S0327, S0435, S0802

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7527?sid=88c40e7b-9c69-4978-b981-03a642ffae27
Protocol(s): S0905

**Lymphoma and Plasma Cell Disorders**

**CALGB/Alliance**

Protocol(s): CALGB-50403

Protocol(s): CALGB-50803

**ECOG**

Advani RH, Li H, Hong F, Kahl BS, Varma G, Boussetta S, Pfeundschuh M, Ziepert M, Coiffier B: Elderly International Prognostic Index in Diffuse Large B-Cell Lymphoma patients > 60 years treated with RCHOP: international validation study using data from RICOVER-60 (German High-Grade Non-Hodgkin Lymphoma Study Group) and LNH 98-5 (Groupe d’Etude de Lymphome d’Adultes). Hematol Oncol 2013; 31(1 suppl): 171; Abst. 222.
Other Participant(s) in the Trial: CALGB/Alliance, SWOG
Protocol(s): E4494

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e19517?sid=da80114b-3d87-4cf2-9c5b-0f96320b0c0
Protocol(s): E4A03
Protocol(s): E3404

Protocol(s): E4A03

Other Participant(s) in the Trial: CALGB/Alliance, NCIC Clinical Trials Group, SWOG
Protocol(s): E2496

**SWOG**

Badari AR, Zaid MA, Unger JM, Rimsza LM, Marron M, Fisher RI, Miller TP, Stocek AT: Markers of angiogenesis and hypoxia to cell of origin (COO) subtypes of DLBCL: Correlative studies from S0515, a phase II trial of R-CHOP plus bevacizumab. J Clin Oncol 2013; 31(15 suppl): Abst. 8562. [http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8562?sid=cb6383a0-835d-4792-9e24-cbfa589775c0](http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/8562?sid=cb6383a0-835d-4792-9e24-cbfa589775c0)
Protocol(s): S0515

Protocol(s): S0120

Other Participant(s) in the Trial: CALGB/Alliance, ECOG
Protocol(s): S0816
Melanoma/Skin Cancers

**ECOG**


Protocol(s): E2602


Protocol(s): E1608

**Other Cancer**

**ACRIN**


Protocol(s): ACRIN-6654, ACRIN-6664

**CALGB/Alliance**


Protocol(s): CALGB-40101, CALGB-50303, CALGB-80203, CALGB-80303, CALGB-80405, CALGB-90401


Protocol(s): Multiple Trials

**ECOG**


Protocol(s): E2Z02
http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20520?sid=bf136000-a977-4d01-8455-129ae73eb1c
Protocol(s): E2Z02

NCCTG/Alliance

Protocol(s): N07C2

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9513?sid=f5fbb0b9-873c-412e-9597-3ddc4021a8c9
Protocol(s): N08C3

Protocol(s): N08C3

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d4332bf8-005b-4cb2-a378-921ae4782081&rKey=52268d6b-7335-4aca-9336-653d6c27ffeb&mKey=%7b9d22d28e7-24ab-466f-9c21f6e66b91c7d
Protocol(s): N08C1, N08CA

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2562?sid=755fe5a5-3d26-446d-a0e8a-09ce478bfdb
Protocol(s): N0871

Sarcoma/Bone and Soft Tissue Cancers

Alliance

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/TPS10594?sid=8fb942c2-0fb6-4a7d-a297-12aed046f675
Protocol(s): A091102
COG

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/2538?sid=81659e6b-89a5-4e39-af0f-34f90765b1f2
Protocol(s): ADVL1115

NCIC Clinical Trials Group

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9502?sid=8a5db886-4a84-42c2-821e-7d908ec56fc
Other Participant(s) in the Trial: RTOG
Protocol(s): NCIC CTG SC.20 (RTOG 0433)

RTOG

Protocol(s): RTOG-95-14

NCI Abstracts

Abstracts with DCTD and/or DCP Investigators

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/7508?sid=bea83189-fbee-4190-8a8e-952401aab275
Protocol(s): E1508

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/e20520?sid=bf136000-a977-4d01-8455-129aeec73eb1c
Protocol(s): E2Z02

http://meeting.ascopubs.org/cgi/content/abstract/31/6_suppl/10?sid=0b66a628-dd0a-4bd5-bacb-09fccc1d016a0
Other Participant(s) in the Trial: CALGB/Alliance
Protocol(s): SWOG-9217
Protocol(s): S0000C

http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/1596?sid=b80465e4-a247-4a22-a915-7a427b84709
Protocol(s): N0577

Protocol(s): S0000C

Disclaimer: References to abstracts included in this report are based on information provided to the EMMES Corporation (CTEP/NCI contractor) by the individual Cooperative Groups and may not reflect all abstracts accepted or presented at the indicated meetings. Inclusion of references under specific subheadings for Cooperative Group is based on information provided, associated trials and information in references. References only appear under one disease heading and the Lead Cooperative Group. Other participating Groups are listed separately. Abstracts that cannot be associated with DCTD (CTEP, CIP, RRP or CDP) or DCP sponsored clinical trials or for which required information was not made available are excluded. Abstracts from other relevant symposia in the same time period as the indicated meetings may be included upon agreement and provided the required information is available. Links to online abstracts are provided if they were available at the time of publication, but there is no guarantee that these links will remain active.